ICCC

ImmuCell Corporation [ICCC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ICCC Stock Summary

Top 10 Correlated Stocks

ICCC


In the News

09:30 28 Mar 2024 ICCC

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET

12:15 28 Mar 2024 ICCC

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET

12:00 28 Mar 2024 ICCC

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.

10:00 28 Mar 2024 ICCC

ImmuCell Corporation (ICCC) Q1 2023 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q1 2023 Earnings Conference Call May 12, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports First Quarter 2023 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.

06:30 28 Mar 2024 ICCC

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023. The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results.

12:50 28 Mar 2024 ICCC

ImmuCell Corporation (ICCC) Q4 2022 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports Fiscal Year 2022 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.

11:55 28 Mar 2024 ICCC

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022

Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET

11:37 28 Mar 2024 ICCC

ImmuCell Corporation (ICCC) Q3 2022 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q3 2022 Earnings Conference Call November 22, 2022 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Bobbi Jo Brockmann - Vice President, Sales and Marketing Conference Call Participants Jim Barrett - Barrett Investments Operator Good morning. And welcome to ImmuCell Corporation Reports Third Quarter Fiscal Year 2022 Financial Results Conference Call.

05:00 28 Mar 2024 ICCC

ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference

PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced today it will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

01:13 28 Mar 2024 ICCC

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2022 Results - Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q2 2022 Earnings Conference Call August 12, 2022 9:00 AM ET Company Participants Joe Diaz - Investor Relations Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas - MKH Management Operator Good morning. This is Anthony from Chorus Call and I will be assisting with our conference call this morning.

ICCC Financial details

Company Rating
Sell
Market Cap
40.54M
Income
-5.77M
Revenue
17.47M
Book val./share
-
Cash/share
0.13
Dividend
-
Dividend %
-
Employees
72
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-6.18
Forward P/E
-
PEG
-0.46
P/S
2.39
P/B
1.5
P/C
41.48
P/FCF
-4.56
Quick Ratio
1.2
Current Ratio
3.59
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.75
EPS next Y
-
EPS next Q
1.58
EPS this Y
134.38%
EPS next Y
-
EPS next 5Y
-85.33%
EPS last 5Y
31.6%
Revenue last 5Y
4.95%
Revenue Q/Q
-5.57%
EPS Q/Q
25%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
9.66%
Inst Trans
0.72%
ROA
-14%
ROE
-23%
ROC
-0.15%
Gross Margin
22%
Oper. Margin
-39%
Profit Margin
-39%
Payout
-
Shs Outstand
7.75M
Shs Float
5.55M
-
-
-
-
Target Price
-
52W Range
4.26-6.05
52W High
-10.14%
52W Low
+34.8%
RSI
58
Rel Volume
0.56
Avg Volume
7.69K
Volume
4.3K
Perf Week
5.93%
Perf Month
7.41%
Perf Quarter
-1.06%
Perf Half Y
0.97%
-
-
-
-
Beta
0.591
-
-
Volatility
0.09%, 0.11%
Prev Close
1.92%
Price
5.3918
Change
4.7%

ICCC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.012.132.532.42.26
Net income per share
-0.19-0.14-0.01-0.32-0.75
Operating cash flow per share
0.030.180.13-0.20.35
Free cash flow per share
-0.17-0.38-0.22-0.710.35
Cash per share
1.651.241.340.750
Book value per share
4.253.924.293.920
Tangible book value per share
4.223.894.273.90
Share holders equity per share
4.253.924.293.920
Interest debt per share
1.31.551.391.660
Market cap
35.12M42.92M60.74M47.25M39.44M
Enterprise value
34.77M45.71M60.83M53.93M39.44M
P/E ratio
-27.1-42-778.71-18.94-6.83
Price to sales ratio
2.562.83.162.542.26
POCF ratio
150.3932.6263.66-30.614.62
PFCF ratio
-30.33-15.57-36.71-8.5614.62
P/B Ratio
1.211.521.861.560
PTB ratio
1.211.521.861.560
EV to sales
2.532.983.162.92.26
Enterprise value over EBITDA
-36.44-33.12236.69-23.46-13.11
EV to operating cash flow
148.8834.7463.75-34.9314.62
EV to free cash flow
-30.02-16.58-36.77-9.7714.62
Earnings yield
-0.04-0.020-0.05-0.15
Free cash flow yield
-0.03-0.06-0.03-0.120.07
Debt to equity
0.290.380.320.410
Debt to assets
0.220.270.230.280
Net debt to EBITDA
0.37-2.020.35-2.910
Current ratio
5.295.56.424.560
Interest coverage
-2.21-3.34-7.01-6.740
Income quality
-0.18-1.29-12.190.620
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.120.110.090.120
Research and developement to revenue
0.270.280.220.240.25
Intangibles to total assets
0.010000
Capex to operating cash flow
-5.96-3.1-2.732.570
Capex to revenue
-0.1-0.27-0.14-0.210
Capex to depreciation
-0.61-1.74-1.06-1.60
Stock based compensation to revenue
0.020.020.010.010
Graham number
4.263.5315.330
ROIC
-0.03-0.03-0.06-0.050
Return on tangible assets
-0.03-0.030-0.060
Graham Net
0.6-0.10.25-0.560
Working capital
10.69M9.95M13.73M10.92M0
Tangible asset value
28.78M28.07M32.41M30.23M0
Net current asset value
3.49M73.01K4.38M-486.24K0
Invested capital
0.290.380.320.410
Average receivables
1.55M1.77M2.29M2.26M900.39K
Average payables
587.96K587.26K673.7K767.52K395K
Average inventory
2.42M2.31M2.59M4.56M3.02M
Days sales outstanding
44.6244.3651.6135.40
Days payables outstanding
29.9125.9325.6926.410
Days of inventory on hand
131.6390.08106.53201.860
Receivables turnover
8.188.237.0710.310
Payables turnover
12.214.0814.2113.820
Inventory turnover
2.774.053.431.810
ROE
-0.04-0.040-0.080
Capex per share
-0.2-0.56-0.34-0.510

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.50.440.460.70.66
Net income per share
-0.22-0.3-0.18-0.12-0.15
Operating cash flow per share
-0.17-0.36-0.09-0.070
Free cash flow per share
-0.36-0.44-0.18-0.120
Cash per share
0.750.40.190.260.13
Book value per share
3.923.643.473.360
Tangible book value per share
3.93.623.453.345.65
Share holders equity per share
3.923.643.473.360
Interest debt per share
1.621.721.962.170
Market cap
47.26M39.97M38.73M41.37M39.45M
Enterprise value
53.94M50.1M52.38M56.06M38.47M
P/E ratio
-7.08-4.32-7.02-11-8.65
Price to sales ratio
12.0811.610.967.677.74
POCF ratio
-36.41-14.47-56.84-81.470
PFCF ratio
-16.95-11.61-27.87-44.560
P/B Ratio
1.561.421.441.590
PTB ratio
1.561.421.441.590
EV to sales
13.7914.5414.8310.397.55
Enterprise value over EBITDA
-31.11-32.15-86.32-47.35-120.97
EV to operating cash flow
-41.57-18.14-76.87-110.410
EV to free cash flow
-19.35-14.55-37.69-60.390
Earnings yield
-0.04-0.06-0.04-0.02-0.03
Free cash flow yield
-0.06-0.09-0.04-0.020
Debt to equity
0.410.470.560.640
Debt to assets
0.280.310.340.370
Net debt to EBITDA
-3.86-6.5-22.49-12.413.08
Current ratio
4.563.192.613.590
Interest coverage
-19-25.07-15.05-8.710
Income quality
0.781.190.490.540
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.150.160.150.10
Research and developement to revenue
0.270.320.310.210.21
Intangibles to total assets
00000
Capex to operating cash flow
1.150.251.040.830
Capex to revenue
-0.38-0.2-0.2-0.080
Capex to depreciation
-2.47-1.04-1.03-0.60
Stock based compensation to revenue
0.020.030.020.020
Graham number
4.364.943.733.030
ROIC
-0.04-0.05-0.03-0.030
Return on tangible assets
-0.04-0.05-0.03-0.02-0.03
Graham Net
-0.56-0.92-1.39-1.460.13
Working capital
10.92M8.41M6.75M8.63M979K
Tangible asset value
30.23M28.01M26.71M25.87M43.81M
Net current asset value
-486.24K-2.71M-6.2M-6.57M979K
Invested capital
0.410.470.560.640
Average receivables
1.77M1.97M1.83M1.77M1M
Average payables
774.67K792.43K856.63K849.12K389.92K
Average inventory
5.68M6.18M6.93M7.46M3.69M
Days sales outstanding
41.4455.9438.7733.510
Days payables outstanding
24.3622.7433.21170
Days of inventory on hand
186.21181.05272.52160.960
Receivables turnover
2.171.612.322.690
Payables turnover
3.693.962.715.30
Inventory turnover
0.480.50.330.560
ROE
-0.05-0.08-0.05-0.040
Capex per share
-0.19-0.09-0.09-0.050

ICCC Frequently Asked Questions

What is ImmuCell Corporation stock symbol ?

ImmuCell Corporation is a US stock , located in Portland of Me and trading under the symbol ICCC

What is ImmuCell Corporation stock quote today ?

ImmuCell Corporation stock price is $5.3918 today.

Is ImmuCell Corporation stock public?

Yes, ImmuCell Corporation is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap